Halozyme Therapeutics (HALO) Set to Announce Quarterly Earnings on Tuesday

Halozyme Therapeutics (NASDAQ:HALO) is scheduled to release its earnings data after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of $0.64 per share for the quarter. Halozyme Therapeutics has set its FY24 guidance at $3.55 to $3.90 EPS and its FY 2024 guidance at 3.550-3.900 EPS.Individual interested in registering for the company’s earnings conference call can do so using this link.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. The firm had revenue of $230.04 million during the quarter, compared to analyst estimates of $235.25 million. On average, analysts expect Halozyme Therapeutics to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock opened at $39.91 on Monday. Halozyme Therapeutics has a 1 year low of $29.85 and a 1 year high of $45.00. The company’s 50-day moving average is $39.99 and its two-hundred day moving average is $37.91. The company has a current ratio of 6.64, a quick ratio of 5.50 and a debt-to-equity ratio of 17.89. The company has a market cap of $5.07 billion, a PE ratio of 18.91, a PEG ratio of 0.47 and a beta of 1.26.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total value of $416,400.00. Following the sale, the senior vice president now owns 156,558 shares of the company’s stock, valued at approximately $6,519,075.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 30,000 shares of company stock worth $1,196,800 over the last ninety days. Company insiders own 2.70% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on HALO shares. JMP Securities reaffirmed a “market outperform” rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, February 21st. StockNews.com upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, February 23rd. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Halozyme Therapeutics in a report on Tuesday, April 30th. The Goldman Sachs Group lowered their price target on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating for the company in a research note on Thursday, January 18th. Finally, Benchmark reissued a “buy” rating and set a $50.00 price objective on shares of Halozyme Therapeutics in a research note on Tuesday, April 16th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $53.29.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.